Binimetinib

MECHANISM OF ACTION

Binimetinib works by inhibiting MEK1 and MEK2 enzymes, which are part of the MAPK/ERK signaling pathway. This pathway normally promotes cell growth and survival. By blocking MEK activity, Binimetinib disrupts the pathway, slowing or stopping the proliferation of cancer cells and inducing cancer cell death.

PHARMACOKINETICS

Absorption

Binimetinib is well absorbed orally, with peak blood levels typically reached 1.5 to 4 hours after ingestion. Food has minimal effect on its absorption, allowing it to be taken with or without meals.

Distribution

Binimetinib has a volume of distribution of approximately 21 liters, indicating moderate distribution into body tissues. About 50–60% of the drug is bound to plasma proteins, which affects how it circulates in the bloodstream and reaches target tissues.

Metabolism

Binimetinib is primarily metabolized in the liver, mainly by the CYP3A4 enzyme. It undergoes oxidative metabolism, producing inactive metabolites that are then eliminated from the body. Liver function can significantly affect the drug’s clearance and dosing.

Excretion

Binimetinib is primarily excreted via the feces (around 81%), with a smaller portion eliminated in urine (about 9%). Its elimination half-life is approximately 8–10 hours, supporting twice-daily oral dosing.

PHARMACODYNAMICS

Binimetinib acts by selectively inhibiting MEK1 and MEK2 kinases, which are key components of the MAPK/ERK signaling pathway. By blocking this pathway, it reduces tumor cell proliferation, survival, and angiogenesis, leading to slowed tumor growth and, in some cases, cancer cell death. Its effects are dose-dependent and most pronounced in tumors with BRAF mutations.

ADMINISTRATION

Binimetinib is administered orally, usually as a tablet taken twice daily. It can be taken with or without food, but doses should be spaced evenly and not missed to maintain consistent drug levels in the body.

DOSAGE AND STRENGTH

Binimetinib is typically prescribed at a dose of 45 mg taken orally twice daily. It is available in 15 mg and 30 mg tablets, allowing flexibility in adjusting the dose based on tolerance and combination therapy requirements.

FOOD INTERACTIONS

Binimetinib has minimal food interactions. It can be taken with or without meals without significantly affecting absorption or effectiveness. However, a consistent routine is recommended to maintain steady drug levels.

DRUG INTERACTIONS

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase Binimetinib levels, raising the risk of side effects.

• CYP3A4 inducers (e.g., rifampin, phenytoin) can decrease its effectiveness.

• Caution is needed with other QT-prolonging drugs or medications affecting liver function, as they may increase cardiac or hepatic risks.

CONTRAINDICATIONS

• Known hypersensitivity to Binimetinib or any of its components.

• Severe hepatic impairment, as liver metabolism is essential for drug clearance.

• Pregnancy, due to potential harm to the fetus.

SIDE EFFECTS

• Common: rash, diarrhea, nausea, fatigue, peripheral edema, and abdominal pain.

• Serious: heart problems (reduced ejection fraction), eye disorders (retinal vein occlusion, blurred vision), elevated liver enzymes, and severe skin reactions.

TOXICITY

Binimetinib can cause toxicity affecting the heart, eyes, liver, and skin. Serious effects include decreased heart function, retinal problems, liver enzyme elevation, and severe rash. Regular monitoring helps manage these risks and ensures safe treatment.